🔗 Share this article

The first new treatments for gonorrhoea in many years are being viewed as a "significant breakthrough" in the effort against drug-resistant strains of the infection, according to researchers.

An International Public Health Issue

The sexually transmitted infection are escalating around the world, with data suggesting more than 82 million infections annually. Particularly high rates are observed in the African continent and nations within the World Health Organization's designated area, which encompasses China and Mongolia to New Zealand. In England, cases have hit a all-time high, while figures across Europe in 2023 were triple the level compared to those in 2014.

“The authorization of fresh medications for gonorrhoea is an important and timely development in the face of growing infection rates, the spread of superbugs and the highly restricted therapeutic options at this time.”

Public health authorities are increasingly worried about the surge in antibiotic-resistant strains. The WHO has designated it as a "high-priority threat". Ongoing monitoring showed that resistance to standard treatments like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

Two New Drugs Receive Approval

Zoliflodacin, marketed under the name a brand name, was cleared by the US FDA in December for use against gonorrhoea. This infection can lead to major issues, including infertility. Scientists anticipate that specific application of this new drug will help hinder the spread of drug resistance.

Gepotidacin, originating from the drugmaker GSK, gained clearance in close succession. This treatment, which is additionally indicated for urinary tract infections, was shown in trials to be effective against superbug versions of the gonorrhoea bacteria.

A Novel Approach to Creation

Zoliflodacin emerged from a innovative non-profit model for antibiotic development. The charitable organization GARDP collaborated with the drug firm its industry partner to develop it.

“This approval represents a major breakthrough in the management of highly resistant gonorrhoea, which until now has been evolving faster than our drug pipeline.”

Research Study Data and Worldwide Availability

As per data released by a prominent scientific publication, the new drug eradicated the vast majority of genital gonorrhoea infections. This places it at an comparable level with the current standard treatment, which combines a dual-drug approach. The study enrolled over 900 patients from multiple nations including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its collaboration, GARDP has the authority to register and commercialise the drug in a wide range of regions with limited resources.

Medical professionals treating patients have voiced hope. Having a easy-to-administer therapy of this kind is described as a "game-changer" for gonorrhoea control. This is deemed essential to lessen the impact of the illness for people and to prevent the spread of untreatable gonorrhoea around the world.